EU/3/13/1108: Orphan designation for the treatment of systemic sclerosis
Table of contents
On 12 March 2013, orphan designation (EU/3/13/1108) was granted by the European Commission to Sanofi-Aventis Groupe, France, for 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid for the treatment of systemic sclerosis.
The sponsorship was transferred to Horizon Therapeutics Ireland Designated Activity Company in September 2020.
Treatment of systemic sclerosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Horizon Therapeutics Ireland Designated Activity Company
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: